JVJean-Thomas Vilquin

Jean-Thomas Vilquin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Thomas Vilquin has a total of 370 co-authors. Here are the top co-authors by number of shared publications:

  • Albert Hagège

    Université Paris Cité, Inserm, PARCC, F-75015 Paris, France

    18 shared publications
  • Ketty Schwartz

    UPMC/AIM UMR S 974, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

    14 shared publications
  • Jean-Pierre Marolleau

    CHU Amiens, Hematology and Cell Therapy Unit, Université Picardie Jules Verne, Amiens, France

    13 shared publications
  • Michel Desnos

    University Paris Descartes, Sorbonne Paris Cité, Paris, France

    12 shared publications
  • Philippe Menasché

    Université René Descartes Paris 5, Faculté de Médecine René Descartes Paris 5, Paris, France

    12 shared publications
  • Patrick Bruneval

    Department of Pathology, Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France

    11 shared publications

Latest Publications

  • Open Access

    Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis

    by Alexandra C. Bayer, Natalia Pinzón, Axel You, Cinthia Bergman, Nadine Dragin, Aurélien Corneau, Frédérique Truffault, Danièle Noël, Christophe Martinaud, Rozen Le Panse, et al.

    Background: Mesenchymal Stromal Cells (MSC) possess innate immunomodulatory properties, which can be significantly enhanced through co-culture with peripheral blood mononuclear cells (PBMC), making them attractive tools for the treatment of autoimmune and inflammatory diseases. Methods: Leveraging a multi-omics approach encompassing RNA sequencing, flow and mass cytometry, secretome analysis, completed by functional evaluations, we investigated the mechanisms underpinning PBMC conditioning of MSC in vitro and their benefits in an animal model of Myasthenia gravis. MSC derived from human adipose tissue were left untreated in resting state (rMSC), conditioned by PBMC (cMSC), or activated by the pro-inflammatory molecule interferon (IFN)-γ (γMSC), then compared for their gene expression profiles, phenotypes and functional capacities. Results: RNA sequencing identified 244 differentially expressed genes in cMSC compared to rMSC, highlighting key immune mediators such as CCL2, CCL11, DPP4, ICAM1, IL6, PDCD1LG2, TNFRSF11B, TNIP1, TNIP3 and ZC3H12A and pinpointing genes involved in matrix remodeling, paracrine and autocrine communications. Comparatively, 2089 genes were differentially expressed between rMSC and γMSC, highlighting host defense, anti-viral response, NFκB signaling pathways modulated by IFN-γ. Flow and mass cytometry analyses revealed upregulation of the surface markers CD26, CD54, and CD273 and intracellular molecules IDO1 and PTGS2 in cMSC. In contrast, IFN-γ activation predominantly increased HLA-related markers while also enhancing the homogeneity of the populations. Together, these results underlined the treatment dependence of transcriptomic and phenotypic signatures. Secretome profiling identified 6 categories of modulated proteins, out of which 22 molecules potentially involved in PBMC conditioning and 40 implicated in cMSC-mediated immunomodulation. Functionally, cMSC induced modulation in PBMC subsets, raising the proportions of lymphocyte populations (CD4 Treg, CD8, B memory), underlining the multimodal effect of conditioning. Also, both a direct cell-cell contact and cMSC supernatants significantly suppressed activated T-cell proliferation in vitro. To confirm immunomodulation efficacy in vivo, cMSC were administrated to our humanized mouse model of Myasthenia Gravis and the treatment significantly halved disease severity from 2 weeks post-injection. Conclusions: This integrative study establishes distinct conditioning signatures, suggests molecular mechanisms, and underscores the therapeutic potential of cMSC, offering a robust framework for advancing cell-based therapies in autoimmune diseases.


  • Open Access

    Les cellules CAR-T

    by Alexandra Bayer Wildberger, Jean-Thomas Vilquin

    Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé


  • Les exosomes, des messagers intercellulaires naturels aux mécanismes polyvalents pour le traitement des myopathies ?

    by Alexandra Bayer-Wildberger, Judith Lorant, Jean-Thomas Vilquin

    Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé


  • Open Access

    The authors reply: Comment on: "Aldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients" by Etienne et al.

    by Jessy Etienne, Pierre Joanne, Cyril Catelain, Stéphanie Riveron, Alexandra Bayer Wildberger, Jérémy Lafable, Isabel Punzon, Stéphane Blot, Onnik Agbulut, Jean‐Thomas Vilquin

  • Open Access

    In vivo stem cell tracking using scintigraphy in a canine model of DMD

    by Inès Barthélémy, Jean-Laurent Thibaud, Pauline de Fornel, Marco Cassano, Isabel Punzón, David Mauduit, Jean-Thomas Vilquin, Patrick Devauchelle, Maurilio Sampaolesi, Stéphane Blot

    One of the main challenges in cell therapy for muscle diseases is to efficiently target the muscle. To address this issue and achieve better understanding of in vivo cell fate, we evaluated the relevance of a non-invasive cell tracking method in the Golden Retriever Muscular Dystrophy (GRMD) model, a well-recognised model of Duchenne Muscular Dystrophy (DMD). Mesoangioblasts were directly labelled with 111In-oxine, and injected through one of the femoral arteries. The scintigraphy images obtained provided the first quantitative mapping of the immediate biodistribution of mesoangioblasts in a large animal model of DMD. The results revealed that cells were trapped by the first capillary filters: the injected limb and the lung. During the days following injection, radioactivity was redistributed to the liver. In vitro studies, performed with the same cells prepared for injecting the animal, revealed prominent cell death and 111In release. In vivo, cell death resulted in 111In release into the vasculature that was taken up by the liver, resulting in a non-specific and non-cell-bound radioactive signal. Indirect labelling methods would be an attractive alternative to track cells on the mid- and long-term.


  • Open Access

    In Vivo Myoblasts Tracking Using the Sodium Iodide Symporter Gene Expression in Dogs

    by Isabel Punzón, David Mauduit, Bryan Holvoet, Jean-Laurent Thibaud, Pauline de Fornel, Christophe M. Deroose, Nicolas Blanchard-Gutton, Jean-Thomas Vilquin, Maurilio Sampaolesi, Inès Barthélémy, et al.


  • Open Access

    Aldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients

    by Jessy Etienne, Pierre Joanne, Cyril Catelain, Stéphanie Riveron, Alexandra Clarissa Bayer, Jérémy Lafable, Isabel Punzon, Stéphane Blot, Onnik Agbulut, Jean‐Thomas Vilquin

    Background: Aldehyde dehydrogenases (ALDHs) are key players in cell survival, protection, and differentiation via the metabolism and detoxification of aldehydes. ALDH activity is also a marker of stem cells. The skeletal muscle contains populations of ALDH‐positive cells amenable to use in cell therapy, whose distribution, persistence in aging, and modifications in myopathic context have not been investigated yet.Methods: The Aldefluor® (ALDEF) reagent was used to assess the ALDH activity of muscle cell populations, whose phenotypic characterizations were deepened by flow cytometry. The nature of ALDH isoenzymes expressed by the muscle cell populations was identified in complementary ways by flow cytometry, immunohistology, and real‐time PCR ex vivo and in vitro. These populations were compared in healthy, aging, or Duchenne muscular dystrophy (DMD) patients, healthy non‐human primates, and Golden Retriever dogs (healthy vs. muscular dystrophic model, Golden retriever muscular dystrophy [GRMD]).Results: ALDEF+ cells persisted through muscle aging in humans and were equally represented in several anatomical localizations in healthy non‐human primates. ALDEF+ cells were increased in dystrophic individuals in humans (nine patients with DMD vs. five controls: 14.9 ± 1.63% vs. 3.6 ± 0.39%, P = 0.0002) and dogs (three GRMD dogs vs. three controls: 10.9 ± 2.54% vs. 3.7 ± 0.45%, P = 0.049). In DMD patients, such increase was due to the adipogenic ALDEF+/CD34+ populations (11.74 ± 1.5 vs. 2.8 ± 0.4, P = 0.0003), while in GRMD dogs, it was due to the myogenic ALDEF+/CD34− cells (3.6 ± 0.6% vs. 1.03 ± 0.23%, P = 0.0165). Phenotypic characterization associated the ALDEF+/CD34− cells with CD9, CD36, CD49a, CD49c, CD49f, CD106, CD146, and CD184, some being associated with myogenic capacities. Cytological and histological analyses distinguished several ALDH isoenzymes (ALDH1A1, 1A2, 1A3, 1B1, 1L1, 2, 3A1, 3A2, 3B1, 3B2, 4A1, 7A1, 8A1, and 9A1) expressed by different cell populations in the skeletal muscle tissue belonging to multinucleated fibres, or myogenic, endothelial, interstitial, and neural lineages, designing them as potential new markers of cell type or of metabolic activity. Important modifications were noted in isoenzyme expression between healthy and DMD muscle tissues. The level of gene expression of some isoenzymes (ALDH1A1, 1A3, 1B1, 2, 3A2, 7A1, 8A1, and 9A1) suggested their specific involvement in muscle stability or regeneration in situ or in vitro.Conclusions: This study unveils the importance of the ALDH family of isoenzymes in the skeletal muscle physiology and homeostasis, suggesting their roles in tissue remodelling in the context of muscular dystrophies.


  • Open Access

    The Muscle Is Not a Passive Target in Myasthenia Gravis

    by Jean-Thomas Vilquin, Alexandra Clarissa Bayer, Rozen Le Panse, Sonia Berrih-Aknin

    Myasthenia gravis (MG) is a rare autoimmune disease mediated by pathogenic antibodies (Ab) directed against components of the neuromuscular junction (NMJ), mainly the acetylcholine receptor (AChR). The etiological mechanisms are not totally elucidated, but they include a combination of genetic predisposition, triggering event(s), and hormonal components. MG disease is associated with defective immune regulation, chronic cell activation, inflammation, and the thymus is frequently abnormal. MG is characterized by muscle fatigability that is very invalidating and can be life-threatening when respiratory muscles are affected. MG is not cured, and symptomatic treatments with acetylcholinesterase inhibitors and immunosuppressors are life-long medications associated with severe side effects (especially glucocorticoids). While the muscle is the ultimate target of the autoimmune attack, its place and role are not thoroughly described, and this mini-review will focus on the cascade of pathophysiologic mechanisms taking place at the NMJ and its consequences on the muscle biology, function, and regeneration in myasthenic patients, at the histological, cellular, and molecular levels. The fine structure of the synaptic cleft is damaged by the Ab binding that is coupled to focal complement-dependent lysis in the case of MG with anti-AChR antibodies. Cellular and molecular reactions taking place in the muscle involve several cell types as well as soluble factors. Finally, the regenerative capacities of the MG muscle tissue may be altered. Altogether, the studies reported in this review demonstrate that the muscle is not a passive target in MG, but interacts dynamically with its environment in several ways, activating mechanisms of compensation that limit the pathogenic mechanisms of the autoantibodies.


  • Open Access

    Long-Term Engraftment (16 Years) of Myoblasts in a Human Infarcted Heart

    by Marie Crahès, Marie-Cécile Bories, Jean-Thomas Vilquin, Jean-Pierre Marolleau, Michel Desnos, Jérôme Larghero, Gilles Soulat, Patrick Bruneval, Albert A. Hagège, Philippe Menasché

    We report the case of a patient who had undergone injections of myoblasts in an infarct area 16 years before being referred for heart transplantation. The pathological examination of the explanted heart found persisting myotubes embedded in fibrosis. This finding supports the ability of myoblasts to survive in harsh environments, which can make them appealing candidates for transplantation in diseases requiring supply of new myogenic cells. Stem Cells Translational Medicine 2018;1–4


  • Modelling human myoblasts survival upon xenotransplantation into immunodeficient mouse muscle

    by Christophe Praud, Karine Vauchez, Pascal Zongo, Jean-Thomas Vilquin